Anti-Phencyclidine [6B5]
Catalogue Number: AB03257-1.29-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | PCP; CI-395; Angel dust; PCE; TCP; phenyl cyclohexyl piperidine; aryl cyclohexylamine; tenocyclidine; 1-(1-phenylcyclohexyl)piperidine; CAS: 77-10-1; CHEBI:8058; mAb6B5; ch6B5; ch-mAb6B5 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 500 ug |
| Host name: | Mouse |
| Clone: | 6B5 |
| Isotype: | |
| Immunogen: | The original antibody was generated from a mouse immunized with a phencyclidine analogue hapten 5-[N-(1'phenylcyclohexyl)amino]pentanoic acid (PCHAP) conjugated to bovine serum albumin. |
| Application: | ELISA, RIA, Ant |
Additional Text
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Application Notes
The binding characterization of this antibody to 3[H]PCP was done using radioimmunoassay. The original IgG1 version of this antibody binds phencyclidine with an affinity of Kd= 1.3 nM. (PMID: 9618414). This antibody was useful in reversing PCP-induced central nervous system toxicity in laboratory animals. The Fab version of this antibody induced antagonism of behavioral effects of repeated intravenous PCP challenges. The Fab completely reversed all PCP-induced locomotor effects in a dose dependent manner. It also completely reversed the locomotor effects induced by two other structurally related potent analogs of PCP: 1-[1-(2-thienyl)cyclohexyl]piperidine and N-ethyl-1-phenylcyclohexylamine (PMID: 9618414). In a rat model for human acute PCP overdose, the antigen-binding fragment (Fab) of mAb6B5 causes a rapid and effective redistribution of PCP out of the brain (PMID: 8768723). This redistribution also produces a rapid recovery from the behavioral toxicity produced by PCP, TCP and PCE in rats (PMID: 8768723; 9618414). Preclinical studies in rats show that mAb6B5 can reverse or reduce the in vivo pharmacological effects of PCP and other potent aryl cyclohexylamines such as TCP. When tested in a rat model based on human chronic PCP use, a single low dose of mAb6B5 provides long-term protection against the adverse effects of PCP and significantly improves the general health status of the animals. Single 1 gm dose of mAb6B5 IgG has the capability of reducing the toxic effects of 1.29gm/day of PCP for 6-8 weeks (PMID: 12829731). The binding characterization of chimeric version of this antibody was done using ELISA (PMID: 18068094). This antibody can be used as an immunotherapeutic agent for PCP and PCP-like drug abuse.
Short Description
This reformatted mouse antibody was made using the variable domain sequences of the original mouse IgG1 format for improved compatibility with existing reagents assays and techniques.
AB03257-1.29-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations